



NuVasive acquires Simplify Medical

February 24, 2021

Safe Harbor Statements

Forward-looking information and non-GAAP measures

NuVasive, Inc. (“NuVasive” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause the Company’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Forward-looking statements include, but are not limited to, statements about the potential benefits of the acquisition, including the expected impact on future financial and operating results, and post-acquisition plans and intentions. The forward-looking statements contained herein are based on the current expectations and assumptions of NuVasive and not on historical facts. The following important factors, among others, could cause actual results to differ materially from those set forth in the forward-looking statements: the loss of key employees; the risk that the businesses will not be integrated successfully; unexpected variations in market growth and demand for the combined company’s products and technologies; and the risk that benefits from the acquisition may not be fully realized or may take longer to realize than expected. Additional risks and uncertainties that may affect future results are described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Management also uses certain non-GAAP financial measures in this presentation, which constitute “non-GAAP financial measures” as defined by the Securities and Exchange Commission. Management uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures can be found on the Investor Relations section of the Company’s website.

Simplify[®] Cervical Artificial Disc

The most clinically effective technology in the cervical total disc replacement (cTDR) procedure segment

Radiologic

Comprises PEEK on ceramic materials, which allows for enhanced visualization through MRI postoperatively compared to competitive devices




Anatomic

Offers anatomically designed disc sizes, with the lowest disc height in the market¹ that more closely matches the native disc height of a wide range of patients



Physiologic

Provides unique articulation which allows a variable center of rotation for each treated level and is designed to closely mimic the motion dynamics of a natural spine segment



Supported by strong clinical data

93%

Overall success rate is statistically superior to anterior cervical discectomy and fusion (ACDF)²

(1) Data on file. Based on review of publicly available materials at the time of this release.
(2) Simplify Cervical Artificial Disc – P200022

1-Level

Received FDA approval for 1-level use in September 2020

2-Level

FDA approval for 2-level indications pending

Expanding NuVasive's growth opportunities

Comprehensive portfolio including procedurally integrated solutions in anterior, posterior, and cervical spine surgery

✓ Anterior

\$900_M

global market opportunity

The X360™ System, powered by Surgical Intelligence™, includes XLIF®, XALIF™, XFixation™

A comprehensive approach to lateral single-position surgery

✓ Posterior

\$1.6_B

global market opportunity

MAS® TLIF and MAS Midline Advanced Materials Science™ implants with proprietary surface and structural technologies designed to enhance fusion

✓ Cervical


\$2.6_B

global market opportunity

Simplify Cervical Artificial Disc advances NuVasive's commitment to provide best-in-class technology in the **C360™ portfolio**

NuVasive Anterior Cervical Plating (ACP) system features the thinnest plate in the market¹ at 1.6 mm

Reline® Cervical² is a next-generation posterior cervical fixation system that provides integration with the Reline system



Note: All estimated market size based on iData Research market reports

(1) Data on file. Based on review of publicly available materials at the time of this release.

(2) Reline Cervical is not yet commercially available. The timeline for availability cannot be guaranteed.

Transaction overview

- ✓ Performance structured terms

**\$150_M upfront payment
using cash on hand**

and milestone payments based on regulatory approval and net sales from products incorporating the Simplify Cervical Artificial Disc technology

- ✓ Financials accelerate long-term growth and margin profile

**Accretive to
non-GAAP diluted EPS
in 2022**

**Differentiated
technology**

- ✓ Transaction delivers on our M&A criteria



The acquisition of Simplify Medical advances our long-term strategy...



...and our commitments to shareholders, surgeons, providers, and patients.



Transform surgery.



Advance care.



Change lives.